We've recently interviewed six key players from the life sciences real estate industry, each offering unique insights into a market that's buzzing with change and growth.
In this piece, we'll distill their collective knowledge into an easy-to-digest overview, aiming to give you a clear view of where this industry is headed in 2024.
Thanks to our six interviewees: Martina La Vista of Lendlease, Rob Beacroft of Lateral, Roger Madelin of British Land, Toğrul Gönden of DRIVEN Investment, Artem Korolev of Mission Street, and George Fraser-Harding of Aviva Investors.
Here is what we learned from them:
Resilience is a recurring theme
A recurring theme is the sector's emergence as a resilient investment opportunity, fuelled by demographic shifts and a growing focus on health and technology. The interviews underscore the unique challenges and prospects of the sector, highlighting the need for operational intensity, innovative development strategies, and a user-centric approach.
Six key aspects that contribute to this theme are:
